This also supports the finding that the cardiovascular benefits are not restricted to those agents structurally similar to human GLP-1 but are more likely a class effect that is seen in all GLP-1RAs
With so many alternatives on the market, copycats threaten to pose an added risk and confusion for consumers
Our bodies naturally produce short-chain amino acids
It is easy to see, easy to pinch, and comfortable for people who prefer sitting down during an injection
PHD3, for example, does not hydroxylate proline 402 within the oxygen-dependent degradation domain of HIF-1, while PHD1 and 2 do so efficiently
The challenge is whether the final serving size, taste, texture, cost, and label claims are commercially realistic